Unknown

Dataset Information

0

Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy.


ABSTRACT:

Background

A combination of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard first-line therapy for diffuse large B cell lymphoma (DLBCL), the most common aggressive lymphoma in adults. One of the major adverse effects of this regimen is vincristine-induced polyneuropathy which leads to discontinuation of vincristine in up to 30% of DLBCL-patients. Dose reduction of vincristine might worsen treatment outcomes of DLBCL but identification of treatment alternatives for patients exhibiting peripheral neuropathy during R-CHOP is an unmet need in hematology.

Methods

In this retrospective cohort study, comprising 987 patients with de novo DLBCL, we delineated the role of vinorelbine as a substitute for vincristine in R-CHOP by measuring improvements in neuropathy and outcome variables.

Results

Five-year overall survival (OS) and progression-free survival (PFS) were 72.6% and 63.1% in patients who received regular doses of vincristine, as compared to 60.6% and 51.7% in patients who received reduced doses of vincristine (p = 0.022 and p = 0.003, respectively). Of 199 patients who switched to vinorelbine, the majority experienced an improvement of neuropathy Furthermore, vinorelbine-switched patients showed favorable oncologic outcomes.

Conclusion

Replacement of vincristine by vinorelbine due to neuropathy is effective and safe, and results in a significant improvement in neuropathy as compared to treatment with R-CHOP.

SUBMITTER: Hatzl S 

PROVIDER: S-EPMC8295169 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3204728 | biostudies-literature
| S-EPMC6457225 | biostudies-literature
| S-EPMC5126263 | biostudies-literature
| S-EPMC7970687 | biostudies-literature
| S-EPMC4833756 | biostudies-literature
| S-EPMC8377611 | biostudies-literature
| S-EPMC6275272 | biostudies-literature
| S-EPMC9321338 | biostudies-literature
| S-EPMC8076791 | biostudies-literature
2023-03-11 | PXD036735 | Pride